Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer SignatureGlobeNewsWire · 3 hr ago
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled DiscoveryGlobeNewsWire · 6 days ago
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026GlobeNewsWire · Oct 5, 2026
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thGlobeNewsWire · Aug 3, 2026Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.02 | $0.00 | Beat |
| May 14, 2026 | -$0.02 | -$0.00 | Beat |
| Apr 15, 2026 | -$0.02 | $0.59 | Beat |
| Nov 17, 2025 | – | -$0.00 | |
| Aug 13, 2025 | – | $0.00 | |
| May 15, 2025 | – | -$0.00 |